Published in J Thromb Haemost on January 01, 2014
The cytoprotective protein C pathway. Blood (2006) 5.75
Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev (2008) 5.34
Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med (2002) 3.91
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med (2007) 3.35
Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem (2001) 3.31
Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest (1987) 3.29
Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res (2001) 2.98
Heme oxygenase-1-derived carbon monoxide enhances the host defense response to microbial sepsis in mice. J Clin Invest (2008) 2.04
Heme oxygenase-1-mediated autophagy protects against hepatocyte cell death and hepatic injury from infection/sepsis in mice. Hepatology (2011) 1.61
Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci (2011) 1.53
Protein C activation following coronary artery occlusion in the in situ porcine heart. Circulation (1991) 1.50
Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest (2010) 1.41
Leukocytes and the natural history of deep vein thrombosis: current concepts and future directions. Arterioscler Thromb Vasc Biol (2011) 1.39
The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest (2010) 1.36
Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J Neurosci (2008) 1.33
New insights into the mechanisms of venous thrombosis. J Clin Invest (2012) 1.32
Haem oxygenase-1: non-canonical roles in physiology and pathology. Clin Sci (Lond) (2012) 1.19
An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke (2012) 1.18
Activated protein C protects against myocardial ischemic/reperfusion injury through AMP-activated protein kinase signaling. J Thromb Haemost (2011) 1.18
Activated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytes. J Immunol (2008) 1.09
Activated protein C and acute kidney injury: Selective targeting of PAR-1. Curr Drug Targets (2009) 1.01
Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des (2012) 0.98
Post-thrombotic syndrome: a clinical review. J Thromb Haemost (2013) 0.97
Induction of heme oxygenase-1 is a beneficial response in a murine model of venous thrombosis. Am J Pathol (2008) 0.94
Heme oxygenase-1 induction improves ischemic renal failure: role of nitric oxide and peroxynitrite. Am J Physiol Heart Circ Physiol (2007) 0.94
Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. Am J Med (2005) 0.93
Genetic variation in heme oxygenase 1 (HMOX1) and the risk of recurrent venous thromboembolism. J Vasc Surg (2008) 0.88
Up-regulation of heme oxygenase-1 attenuates brain damage after cerebral ischemia via simultaneous inhibition of superoxide production and preservation of NO bioavailability. Exp Neurol (2012) 0.87
Activated protein C accelerates venous thrombus resolution through heme oxygenase-1 induction. J Thromb Haemost (2014) 0.85
Increased risk of venous thromboembolism is associated with genetic variation in heme oxygenase-1 in Blacks. Thromb Res (2012) 0.81
Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. N Engl J Med (1994) 4.00
Deficiency of protein C in congenital thrombotic disease. J Clin Invest (1981) 3.56
Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology. Proc Natl Acad Sci U S A (1999) 2.87
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol (1999) 2.56
A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A (1997) 2.22
Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem (1977) 1.86
Plasma protein S deficiency in familial thrombotic disease. Blood (1984) 1.82
Human high molecular weight kininogen. Studies of structure-function relationships and of proteolysis of the molecule occurring during contact activation of plasma. J Biol Chem (1979) 1.72
American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med (2001) 1.70
Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation (2001) 1.67
Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. J Clin Invest (1980) 1.61
Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci U S A (1976) 1.59
Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood (1982) 1.58
The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest (1977) 1.55
Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet (1983) 1.53
Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells. J Clin Invest (1980) 1.53
Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood (1984) 1.52
Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. Proc Natl Acad Sci U S A (1977) 1.52
Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation (1990) 1.52
Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem (1993) 1.51
Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation (1991) 1.47
Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci U S A (1978) 1.46
Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood (2001) 1.46
Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. Eur Heart J (2002) 1.43
Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med (2000) 1.40
Impairments of the protein C system and fibrinolysis in infection-associated stroke. Stroke (1996) 1.38
The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol (1982) 1.34
Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood (1981) 1.34
Human factor XII (Hageman factor). Methods Enzymol (1976) 1.31
Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood (1982) 1.30
Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood (1991) 1.28
Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci U S A (1985) 1.27
Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med (1978) 1.26
Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci U S A (1994) 1.25
Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet (1994) 1.23
Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest (1993) 1.17
The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost (1988) 1.17
Direct detection of activated protein C in blood from human subjects. Blood (1992) 1.17
Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood (1994) 1.16
Alteration of fibrin network by activated protein C. Blood (1994) 1.16
Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood (1986) 1.15
Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2. J Thromb Haemost (2008) 1.13
Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease. Ann Rheum Dis (2004) 1.13
Physiologic inhibition of human activated protein C by alpha 1-antitrypsin. J Biol Chem (1988) 1.11
Purification and characterization of plasma protein C inhibitor. Thromb Res (1989) 1.10
Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost (2006) 1.10
Sulfatide-dependent autoactivation of human blood coagulation Factor XII (Hageman Factor). J Biol Chem (1983) 1.09
Clinical studies of protein C. Semin Thromb Hemost (1984) 1.09
Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood (1995) 1.09
Total chemical synthesis of enzymatically active human type II secretory phospholipase A2. Proc Natl Acad Sci U S A (1997) 1.08
Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry (1980) 1.08
Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood (1989) 1.08
Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358. J Biol Chem (1990) 1.08
A structural model for the prostate disease marker, human prostate-specific antigen. Protein Sci (1994) 1.05
Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. Protein Sci (1997) 1.04
Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest (1979) 1.04
Isolation and functional characterization of the active light chain of activated human blood coagulation factor XI. J Biol Chem (1983) 1.04
The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur J Biochem (1992) 1.03
Identification and quantitation of protein S in human platelets. Blood (1985) 1.02
Blood coagulation. The thrombin paradox. Nature (1995) 1.02
An alternative extrinsic pathway of human blood coagulation. Blood (1982) 1.02
Identification of a sequence of human activated protein C (residues 390-404) essential for its anticoagulant activity. J Biol Chem (1991) 1.01
Receptors for high molecular weight kininogen on stimulated washed human platelets. Biochemistry (1984) 1.00
Isolation and characterization of the gene encoding 2,3-oxidosqualene-lanosterol cyclase from Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1994) 1.00
Human blood coagulation factor IX. Purification, properties, and mechanism of activation by activated factor XI. J Biol Chem (1978) 0.99
Immunochemical studies of human high molecular weight kininogen and of its complexes with plasma prekallikrein or kallikrein. J Biol Chem (1980) 0.99
Binding of coagulation factor XI to washed human platelets. Biochemistry (1986) 0.99
A novel exosite in the light chain of human activated protein C essential for interaction with blood coagulation factor Va. Biochemistry (1993) 0.98
The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. Blood (2000) 0.98
Immunoblotting studies of the molecular forms of protein C in plasma. Thromb Res (1988) 0.97
Rabbit blood coagulation factor XI. Purification and properties. Thromb Res (1979) 0.97
A protein S deficient family with portal vein thrombosis. Thromb Haemost (1985) 0.96
Autoactivation of human plasma prekallikrein. J Biol Chem (1987) 0.96
Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor. Proc Natl Acad Sci U S A (1990) 0.96
Conformational changes in aspartate trancarbamylase. I. Studies of ligand binding and of subunit interactions by circular dichroism spectroscopy. J Biol Chem (1972) 0.95
Cardiolipin is a normal component of human plasma lipoproteins. Proc Natl Acad Sci U S A (2000) 0.95
Immunological studies of prekallikrein, kallikrein, and high-molecular-weight kininogen in normal and deficient plasmas and in normal plasma after cold-dependent activation. J Lab Clin Med (1980) 0.94
Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays. J Thromb Haemost (2006) 0.94
Human protein C: inactivation of factors V and VIII in plasma by the activated molecule. Ann N Y Acad Sci (1981) 0.94
Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome. Ann Intern Med (1996) 0.93
A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood (1997) 0.93
Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va. Protein Sci (1996) 0.92
Recent advances in the understanding of contact activation reactions. Semin Thromb Hemost (1979) 0.92
A comparison of the abilities of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen. Thromb Res (1983) 0.92
Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity. Proc Natl Acad Sci U S A (1997) 0.92
Isolated canine mastocytoma cells: propagation and characterization of two cell lines. Am J Physiol (1986) 0.91
Taste preferences of the common vampire bat (Desmodus rotundus). J Chem Ecol (1982) 0.91
Molecular assembly in the contact phase of the Hageman factor system. Am J Med (1979) 0.91
Conformational changes in aspartate transcarbamylase. II. Circular dichroism evidence for the involvement of metal ions in allosteric interactions. J Biol Chem (1973) 0.91
Identification of divalent metal ion-dependent inhibition of activated protein C by alpha 2-macroglobulin and alpha 2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin. J Biol Chem (1991) 0.91
Orientation of the putative recognition helix in the DNA-binding domain of Hin recombinase complexed with the hix site. Biochemistry (1990) 0.91
Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. J Biol Chem (1987) 0.91
Interaction of S-protein of complement with thrombin and antithrombin III during coagulation. Protection of thrombin by S-protein from antithrombin III inactivation. J Biol Chem (1986) 0.90
Urate crystal--dependent cleavage of Hageman factor in human plasma and synovial fluid. J Lab Clin Med (1980) 0.90
Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob Agents Chemother (2001) 0.90
Limited generation of activated protein C during infusion of the protein C activator thrombin analog W215A/E217A in primates. J Thromb Haemost (2006) 0.90
Binding site for blood coagulation factor Xa involving residues 311-325 in factor Va. J Biol Chem (1998) 0.89
Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood (1986) 0.88
Isolation and functional properties of the heavy and light chains of human plasma kallikrein. J Biol Chem (1982) 0.88